DUBLIN--(http://www.researchandmarkets.com/research/224cpn/osteoporosis) has announced the addition of Decision Resources, Inc's new report "Osteoporosis (Event Driven)" to their offering.)--Research and Markets (
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in the osteoporosis market for therapies that are safer and more efficacious, particularly in reducing the risk of nonvertebral fractures. The launch of key new therapies, coupled with changes in treatment guidelines and in physician prescribing behavior, will lead to important market changes over the 2010-2020 forecast period.
The osteoporosis and osteopenia market is maturing in the United States and Europe, but Japan remains an important driver of growth. The recent launch of several drugs in Japanincluding daily and weekly formulations of teriparatide (Eli Lilly's Forteo/Forsteo and Asahi Kasei's Teribone, respectively), bazedoxifene (Pfizer's Viviant), and a monthly formulation of minodronate (Ono/Astellas's Recalbon/Bonoteo)have dramatic implications for that country's market.
In this report, we analyze uptake of these drugs over the next several years and the implications for other drugs in the Japanese market, such as alendronate (Merck/Teijin's Fosamax/Bonalon, generics) and risedronate (Sanofi/Warner Chilcott/Eisai's Actonel/Atelvia, Takeda's Benet, generics).
Key Topics Covered:
- Executive Summary
- 1 Etiology and Pathophysiology
- 2 Epidemiology and Patient Populations
- 3 Current Therapies and Medical Practice
- 4 Unmet Needs
- 5 Emerging Therapies
- 6 Market Outlook
- Tables and Figures
For more information visit http://www.researchandmarkets.com/research/224cpn/osteoporosis
Source: Decision Resources, Inc